Citizens Jmp Issues Positive Forecast for Halozyme Therapeutics (NASDAQ:HALO) Stock Price

Posted by Brian Himes on Nov 7th, 2026

Halozyme Therapeutics (NASDAQ:HALO – Free Report) had its price objective hoisted by Citizens Jmp from $93.00 to $149.00 in a report released on Friday morning,Benzinga reports. The brokerage currently has a market outperform rating on the biopharmaceutical company’s stock.

Several other equities research analysts also recently weighed in on HALO. Zacks Research upgraded shares of Halozyme Therapeutics from a “hold” rating to a “strong-buy” rating in a research note on Tuesday, October 13th. HC Wainwright raised their price objective on shares of Halozyme Therapeutics from $115.00 to $130.00 and gave the company a “buy” rating in a research report on Wednesday, October 7th. JPMorgan Chase & Co. boosted their target price on Halozyme Therapeutics from $78.00 to $79.00 and gave the stock a “neutral” rating in a research report on Tuesday. Citigroup reissued a “market outperform” rating on shares of Halozyme Therapeutics in a research note on Friday, August 7th. Finally, Weiss Ratings raised Halozyme Therapeutics from a “buy (b-)” rating to a “buy (b)” rating in a report on Monday, August 31st. One research analyst has rated the stock with a Strong Buy rating, nine have given a Buy rating, two have issued a Hold rating and one has assigned a Sell rating to the stock. According to data from MarketBeat.com, the stock has an average rating of “Moderate Buy” and a consensus price target of $106.09.

Get Our Latest Research Report on HALO

Halozyme Therapeutics Stock Performance

Shares of HALO traded down $19.33 during mid-day trading on Friday, reaching $103.63. 6,162,578 shares of the company’s stock were exchanged, compared to its average volume of 2,186,879. The business’s fifty day simple moving average is $115.19 and its 200-day simple moving average is $84.73. The stock has a market capitalization of $11.76 billion, a PE ratio of 26.37, a price-to-earnings-growth ratio of 0.49 and a beta of 0.92. Halozyme Therapeutics has a 52-week low of $61.22 and a 52-week high of $134.00. The company has a debt-to-equity ratio of 13.50, a current ratio of 2.71 and a quick ratio of 2.31.

Halozyme Therapeutics (NASDAQ:HALO – Get Free Report) last issued its quarterly earnings results on Thursday, November 5th. The biopharmaceutical company reported $2.39 earnings per share for the quarter, topping analysts’ consensus estimates of $2.30 by $0.09. Halozyme Therapeutics had a net margin of 24.86% and a return on equity of 260.98%. The firm had revenue of $492.97 million during the quarter, compared to analysts’ expectations of $491.63 million. During the same quarter in the prior year, the business earned $1.72 EPS. Halozyme Therapeutics’s quarterly revenue was up 39.1% compared to the same quarter last year. On average, equities research analysts expect that Halozyme Therapeutics will post 8.32 earnings per share for the current year.

Insider Activity at Halozyme Therapeutics

In related news, Director Matthew L. Posard sold 5,230 shares of the firm’s stock in a transaction that occurred on Thursday, October 1st. The shares were sold at an average price of $108.54, for a total transaction of $567,664.20. Following the sale, the director owned 53,609 shares in the company, valued at approximately $5,818,720.86. This trade represents a 8.89% decrease in their ownership of the stock. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through this hyperlink. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, CEO Helen Torley sold 20,000 shares of Halozyme Therapeutics stock in a transaction on Thursday, October 8th. The shares were sold at an average price of $109.40, for a total value of $2,188,000.00. Following the completion of the sale, the chief executive officer directly owned 767,780 shares of the company’s stock, valued at approximately $83,995,132. This represents a 2.54% decrease in their position. The disclosure for this sale is available in the SEC filing. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. In the last 90 days, insiders have sold 125,852 shares of company stock valued at $13,538,046. 2.50% of the stock is owned by corporate insiders.

Institutional Investors Weigh In On Halozyme Therapeutics

A number of institutional investors have recently added to or reduced their stakes in HALO. Allworth Financial LP increased its position in Halozyme Therapeutics by 3.5% during the 3rd quarter. Allworth Financial LP now owns 38,995 shares of the biopharmaceutical company’s stock worth $4,305,000 after purchasing an additional 1,331 shares in the last quarter. R Squared Ltd acquired a new stake in Halozyme Therapeutics in the third quarter valued at approximately $225,000. Fifth Third Bancorp raised its stake in shares of Halozyme Therapeutics by 52.3% during the third quarter. Fifth Third Bancorp now owns 145,756 shares of the biopharmaceutical company’s stock valued at $16,091,000 after purchasing an additional 50,075 shares during the period. Maryland State Retirement & Pension System raised its stake in shares of Halozyme Therapeutics by 20.9% during the third quarter. Maryland State Retirement & Pension System now owns 7,382 shares of the biopharmaceutical company’s stock valued at $815,000 after purchasing an additional 1,275 shares during the period. Finally, Ritholtz Wealth Management lifted its position in shares of Halozyme Therapeutics by 17.3% during the third quarter. Ritholtz Wealth Management now owns 6,570 shares of the biopharmaceutical company’s stock worth $725,000 after purchasing an additional 971 shares in the last quarter. Hedge funds and other institutional investors own 97.79% of the company’s stock.

More Halozyme Therapeutics News

Here are the key news stories impacting Halozyme Therapeutics this week:

Positive Sentiment: Q3 revenue rose 39% year over year to $493 million and adjusted EPS of $2.39 beat estimates. Record royalty revenue increased 44% to $341 million. Halozyme also raised its 2026 revenue, royalty, EBITDA and adjusted EPS guidance. Q3 results and guidance
Positive Sentiment: The FDA approved Johnson & Johnson’s RYBREVANT FASPRO, which uses Halozyme’s ENHANZE technology, for certain patients with advanced head and neck cancer. The expanded use could support future royalties. FDA approval
Positive Sentiment: Halozyme said its analysis of Medicare’s drug-price negotiation rule indicates zero to minimal impact on royalty revenue through at least 2035, easing a potential long-term concern. Medicare rule assessment
Neutral Sentiment: Citizens JMP raised its price target to $149 and maintained an outperform rating, while Wells Fargo raised its target to $110 but kept an equal-weight rating—signaling differing views on further upside. Citizens JMP rating
Negative Sentiment: Despite the earnings beat and higher guidance, reports noted a negative share reaction and questions around the guidance reset, suggesting results may not have met elevated investor expectations. The Merck patent dispute also remains an investor focus. Earnings reaction and guidance questions

Halozyme Therapeutics Company Profile

(Get Free Report)

Halozyme Therapeutics, Inc is a biopharmaceutical company focused on developing and commercializing drug-delivery technologies that can improve the administration of injectable medicines. The company’s primary platform, ENHANZE, uses a proprietary recombinant human hyaluronidase enzyme to facilitate the subcutaneous delivery of biologic drugs and other injectable therapies that may otherwise require intravenous infusion.

Halozyme licenses its technologies to pharmaceutical and biotechnology companies, which use them in a range of marketed and investigational products.